ID   PKN2_HUMAN              Reviewed;         984 AA.
AC   Q16513; B4DQ21; B4DTP5; B4DVG1; D3DT24; Q08AF4; Q9H1W4;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 175.
DE   RecName: Full=Serine/threonine-protein kinase N2;
DE            EC=2.7.11.13;
DE   AltName: Full=PKN gamma;
DE   AltName: Full=Protein kinase C-like 2;
DE   AltName: Full=Protein-kinase C-related kinase 2;
GN   Name=PKN2; Synonyms=PRK2, PRKCL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=B-cell, and Spleen;
RX   PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Cloning and expression patterns of two members of a novel protein-
RT   kinase-C-related kinase family.";
RL   Eur. J. Biochem. 227:344-351(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 4 AND 5).
RC   TISSUE=Placenta, and Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ENZYME REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-117
RP   AND ASP-700.
RX   PubMed=9368003; DOI=10.1074/jbc.272.47.29449;
RA   Cryns V.L., Byun Y., Rana A., Mellor H., Lustig K.D., Ghanem L.,
RA   Parker P.J., Kirschner M.W., Yuan J.;
RT   "Specific proteolysis of the kinase protein kinase C-related kinase 2
RT   by caspase-3 during apoptosis. Identification by a novel, small pool
RT   expression cloning strategy.";
RL   J. Biol. Chem. 272:29449-29453(1997).
RN   [8]
RP   FUNCTION, INTERACTION WITH RAC1 AND RHOA, AND AUTOPHOSPHORYLATION.
RX   PubMed=9121475; DOI=10.1128/MCB.17.4.2247;
RA   Vincent S., Settleman J.;
RT   "The PRK2 kinase is a potential effector target of both Rho and Rac
RT   GTPases and regulates actin cytoskeletal organization.";
RL   Mol. Cell. Biol. 17:2247-2256(1997).
RN   [9]
RP   FUNCTION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF PHE-974; PHE-977;
RP   ASP-978 AND TYR-979.
RX   PubMed=10226025; DOI=10.1016/S0960-9822(99)80186-9;
RA   Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P.,
RA   Currie R., Downes C.P., Alessi D.R.;
RT   "PDK1 acquires PDK2 activity in the presence of a synthetic peptide
RT   derived from the carboxyl terminus of PRK2.";
RL   Curr. Biol. 9:393-404(1999).
RN   [10]
RP   INTERACTION WITH NCK1 AND NCK2, AND TISSUE SPECIFICITY.
RX   PubMed=10026169; DOI=10.1074/jbc.274.9.5542;
RA   Braverman L.E., Quilliam L.A.;
RT   "Identification of Grb4/Nckbeta, a src homology 2 and 3 domain-
RT   containing adapter protein having similar binding and biological
RT   properties to Nck.";
RL   J. Biol. Chem. 274:5542-5549(1999).
RN   [11]
RP   INTERACTION WITH MAP3K2.
RX   PubMed=10818102; DOI=10.1074/jbc.M003148200;
RA   Sun W., Vincent S., Settleman J., Johnson G.L.;
RT   "MEK kinase 2 binds and activates protein kinase C-related kinase 2.
RT   Bifurcation of kinase regulatory pathways at the level of an MAPK
RT   kinase kinase.";
RL   J. Biol. Chem. 275:24421-24428(2000).
RN   [12]
RP   FUNCTION IN APOPTOSIS, FUNCTION IN AKT1 ACTIVITY INHIBITION, ENZYME
RP   REGULATION, INTERACTION WITH AKT1, AND MUTAGENESIS OF ASP-117 AND
RP   ASP-700.
RX   PubMed=10926925; DOI=10.1074/jbc.M001753200;
RA   Koh H., Lee K.H., Kim D., Kim S., Kim J.W., Chung J.;
RT   "Inhibition of Akt and its anti-apoptotic activities by tumor necrosis
RT   factor-induced protein kinase C-related kinase 2 (PRK2) cleavage.";
RL   J. Biol. Chem. 275:34451-34458(2000).
RN   [13]
RP   PHOSPHORYLATION AT THR-816 BY PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=10792047; DOI=10.1073/pnas.090491897;
RA   Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.;
RT   "Phosphorylation of protein kinase N by phosphoinositide-dependent
RT   protein kinase-1 mediates insulin signals to the actin cytoskeleton.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000).
RN   [14]
RP   INTERACTION WITH PTPN13, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-686 AND CYS-984.
RX   PubMed=11356191; DOI=10.1016/S0014-5793(01)02401-2;
RA   Gross C., Heumann R., Erdmann K.S.;
RT   "The protein kinase C-related kinase PRK2 interacts with the protein
RT   tyrosine phosphatase PTP-BL via a novel PDZ domain binding motif.";
RL   FEBS Lett. 496:101-104(2001).
RN   [15]
RP   FUNCTION IN KINASE ACTIVITY INHIBITION, AND INTERACTION WITH PDPK1.
RX   PubMed=11781095; DOI=10.1021/bi010719z;
RA   Hodgkinson C.P., Sale G.J.;
RT   "Regulation of both PDK1 and the phosphorylation of PKC-zeta and
RT   -delta by a C-terminal PRK2 fragment.";
RL   Biochemistry 41:561-569(2002).
RN   [16]
RP   FUNCTION IN CELL ADHESION, AND INDUCTION.
RX   PubMed=11777936; DOI=10.1083/jcb.200105140;
RA   Calautti E., Grossi M., Mammucari C., Aoyama Y., Pirro M., Ono Y.,
RA   Li J., Dotto G.P.;
RT   "Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in
RT   keratinocyte cell-cell adhesion.";
RL   J. Cell Biol. 156:137-148(2002).
RN   [17]
RP   FUNCTION IN HCV REPLICATION, FUNCTION IN PHOSPHORYLATION OF NS5B, AND
RP   INTERACTION WITH HCV NS5B.
RX   PubMed=15364941; DOI=10.1074/jbc.M408617200;
RA   Kim S.J., Kim J.H., Kim Y.G., Lim H.S., Oh J.W.;
RT   "Protein kinase C-related kinase 2 regulates hepatitis C virus RNA
RT   polymerase function by phosphorylation.";
RL   J. Biol. Chem. 279:50031-50041(2004).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-958, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-302; SER-306 AND
RP   SER-360, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17332740; DOI=10.1038/sj.emboj.7601637;
RA   Schmidt A., Durgan J., Magalhaes A., Hall A.;
RT   "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit
RT   from cytokinesis.";
RL   EMBO J. 26:1624-1636(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [22]
RP   ENZYME REGULATION, INTERACTION WITH PDPK1, AND MUTAGENESIS OF THR-816;
RP   THR-958; PHE-977; ASP-978 AND TYR-979.
RX   PubMed=18835241; DOI=10.1016/j.abb.2008.09.008;
RA   Lim W.G., Chen X., Liu J.P., Tan B.J., Zhou S., Smith A., Lees N.,
RA   Hou L., Gu F., Yu X.Y., Du Y., Smith D., Verma C., Liu K., Duan W.;
RT   "The C-terminus of PRK2/PKNgamma is required for optimal activation by
RT   RhoA in a GTP-dependent manner.";
RL   Arch. Biochem. Biophys. 479:170-178(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-958, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-110; THR-121; THR-124;
RP   SER-302; SER-306; SER-360; SER-362; SER-535; THR-628; SER-631 AND
RP   THR-958, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057;
RA   Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B.,
RA   McKinsey T.A.;
RT   "Protein kinase C-related kinase targets nuclear localization signals
RT   in a subset of class IIa histone deacetylases.";
RL   FEBS Lett. 584:1103-1110(2010).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-302; SER-306; SER-360;
RP   SER-583 AND THR-958, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32]
RP   FUNCTION, INTERACTION WITH RAC1; RHOA AND RHOC, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20974804; DOI=10.1128/MCB.01001-10;
RA   Wallace S.W., Magalhaes A., Hall A.;
RT   "The Rho target PRK2 regulates apical junction formation in human
RT   bronchial epithelial cells.";
RL   Mol. Cell. Biol. 31:81-91(2011).
RN   [33]
RP   FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY.
RX   PubMed=21754995; DOI=10.1371/journal.pone.0021732;
RA   Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S.,
RA   Collazos A., Parker P.J.;
RT   "Regulatory domain selectivity in the cell-type specific PKN-
RT   dependence of cell migration.";
RL   PLoS ONE 6:E21732-E21732(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-360; SER-583;
RP   THR-628 AND THR-958, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-952 AND THR-958, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: PKC-related serine/threonine-protein kinase and Rho/Rac
CC       effector protein that participates in specific signal transduction
CC       responses in the cell. Plays a role in the regulation of cell
CC       cycle progression, actin cytoskeleton assembly, cell migration,
CC       cell adhesion, tumor cell invasion and transcription activation
CC       signaling processes. Phosphorylates CTTN in hyaluronan-induced
CC       astrocytes and hence decreases CTTN ability to associate with
CC       filamentous actin. Phosphorylates HDAC5, therefore lead to impair
CC       HDAC5 import. Direct RhoA target required for the regulation of
CC       the maturation of primordial junctions into apical junction
CC       formation in bronchial epithelial cells. Required for G2/M phases
CC       of the cell cycle progression and abscission during cytokinesis in
CC       a ECT2-dependent manner. Stimulates FYN kinase activity that is
CC       required for establishment of skin cell-cell adhesion during
CC       keratinocytes differentiation. Regulates epithelial bladder cells
CC       speed and direction of movement during cell migration and tumor
CC       cell invasion. Inhibits Akt pro-survival-induced kinase activity.
CC       Mediates Rho protein-induced transcriptional activation via the c-
CC       fos serum response factor (SRF). Phosphorylates HCV NS5B leading
CC       to stimulation of HCV RNA replication.
CC       {ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:10926925,
CC       ECO:0000269|PubMed:11777936, ECO:0000269|PubMed:11781095,
CC       ECO:0000269|PubMed:15364941, ECO:0000269|PubMed:17332740,
CC       ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:20974804,
CC       ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:9121475}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Kinase activity is activated upon binding to
CC       GTP-bound Rhoa/Rac1 GTPases. Activated by caspase-3 (CASP3)
CC       cleavage during apoptosis. Activated by lipids, particularly
CC       cardiolipin and to a lesser extent by other acidic phospholipids
CC       and unsaturated fatty acids. Two specific sites, Thr-816
CC       (activation loop of the kinase domain) and Thr-958 (turn motif),
CC       need to be phosphorylated for its full activation.
CC       {ECO:0000269|PubMed:10926925, ECO:0000269|PubMed:18835241,
CC       ECO:0000269|PubMed:9368003}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=15.83 uM for HDAC5 {ECO:0000269|PubMed:20188095};
CC   -!- SUBUNIT: Interacts (via the REM repeats) with RHOA (GTP-bound form
CC       preferentially). Interacts (via the REM repeats) with RAC1 (GTP-
CC       bound form preferentially). Interacts with NCK1 (via SH3 domains).
CC       Interacts with CD44 (By similarity). Interacts with RHOA (GTP-
CC       bound form preferentially) and RAC1 (GTP-bound form
CC       preferentially); the interactions induce its autophosphorylation.
CC       Interacts (via C-terminal kinase domain) with PDPK1; the
CC       interaction stimulates PDPK1 kinase activity. Interacts with
CC       MAP3K2; the interaction activates PRK2 kinase activity in a
CC       MAP3K2-independent kinase activity. Interacts (via C-terminal
CC       domain) with AKT1; the interaction occurs with the C-terminal
CC       cleavage product of PRK2 in apoptotic cells. Interacts (via C-
CC       terminus) with PTPN13 (via PDZ 3 domain). Interacts with HCV NS5B
CC       (via N-terminal finger domain). Interacts with NCK1, NCK2 and
CC       RHOC. {ECO:0000250, ECO:0000269|PubMed:10026169,
CC       ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:10792047,
CC       ECO:0000269|PubMed:10818102, ECO:0000269|PubMed:10926925,
CC       ECO:0000269|PubMed:11356191, ECO:0000269|PubMed:11781095,
CC       ECO:0000269|PubMed:15364941, ECO:0000269|PubMed:18835241,
CC       ECO:0000269|PubMed:20974804, ECO:0000269|PubMed:9121475}.
CC   -!- INTERACTION:
CC       O92972:- (xeno); NbExp=7; IntAct=EBI-2511350, EBI-10006231;
CC       Q15118:PDK1; NbExp=6; IntAct=EBI-2511350, EBI-7016221;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11356191,
CC       ECO:0000269|PubMed:17332740}. Nucleus
CC       {ECO:0000269|PubMed:11356191}. Membrane
CC       {ECO:0000250|UniProtKB:Q8BWW9}. Cell projection, lamellipodium
CC       {ECO:0000269|PubMed:11356191}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:11356191}. Cleavage furrow
CC       {ECO:0000269|PubMed:17332740}. Midbody
CC       {ECO:0000269|PubMed:17332740}. Cell junction
CC       {ECO:0000269|PubMed:20974804}. Note=Colocalizes with PTPN13 in
CC       lamellipodia-like structures, regions of large actin turnover.
CC       Accumulates during telophase at the cleavage furrow and
CC       concentrates finally around the midbody in cytokinesis. Recruited
CC       to nascent cell-cell contacts at the apical surface of cells. In
CC       the course of viral infection, colocalizes with HCV NS5B at
CC       perinuclear region in the cytoplasm. {ECO:0000269|PubMed:11356191,
CC       ECO:0000269|PubMed:17332740}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q16513-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16513-2; Sequence=VSP_042183;
CC       Name=3;
CC         IsoId=Q16513-3; Sequence=VSP_042184;
CC       Name=4;
CC         IsoId=Q16513-4; Sequence=VSP_042181;
CC       Name=5;
CC         IsoId=Q16513-5; Sequence=VSP_042180, VSP_042182;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Expressed in numerous tumor cell
CC       lines, especially in bladder tumor cells.
CC       {ECO:0000269|PubMed:10026169, ECO:0000269|PubMed:21754995}.
CC   -!- INDUCTION: Up-regulated during keratinocyte differentiation.
CC       {ECO:0000269|PubMed:11777936}.
CC   -!- DOMAIN: The N-terminal regioninterferes with the interaction
CC       between AKT1 and the C-terminal regionof PKN2.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC   -!- DOMAIN: The apoptotic C-terminal cleavage product inhibits EGF-
CC       induced kinase activity of AKT1 phosphorylation at 'Thr-308' and
CC       'Ser-473' sites, PDPK1 autophosphorylation and kinases PRKCD and
CC       PRKCZ phosphorylations.
CC   -!- PTM: Autophosphorylated. Phosphorylated during mitosis.
CC       {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}.
CC   -!- PTM: Activated by limited proteolysis with trypsin (By
CC       similarity). Proteolytically cleaved by caspase-3 during the
CC       induction of apoptotic cell death. {ECO:0000250,
CC       ECO:0000269|PubMed:9368003}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U33052; AAC50208.1; -; mRNA.
DR   EMBL; S75548; AAB33346.1; -; mRNA.
DR   EMBL; AK298595; BAG60783.1; -; mRNA.
DR   EMBL; AK300304; BAG62057.1; -; mRNA.
DR   EMBL; AK301066; BAG62673.1; -; mRNA.
DR   EMBL; AL136381; CAI23271.1; -; Genomic_DNA.
DR   EMBL; AC119426; CAI23271.1; JOINED; Genomic_DNA.
DR   EMBL; CH471097; EAW73161.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73164.1; -; Genomic_DNA.
DR   EMBL; BC125199; AAI25200.1; -; mRNA.
DR   CCDS; CCDS714.1; -. [Q16513-1]
DR   CCDS; CCDS81350.1; -. [Q16513-3]
DR   PIR; S67527; S67527.
DR   RefSeq; NP_001307636.1; NM_001320707.1. [Q16513-3]
DR   RefSeq; NP_001307637.1; NM_001320708.1. [Q16513-4]
DR   RefSeq; NP_001307638.1; NM_001320709.1. [Q16513-2]
DR   RefSeq; NP_006247.1; NM_006256.3. [Q16513-1]
DR   RefSeq; XP_011540074.1; XM_011541772.2. [Q16513-5]
DR   UniGene; Hs.440833; -.
DR   PDB; 4CRS; X-ray; 2.75 A; A=646-984.
DR   PDB; 4RRV; X-ray; 1.41 A; B=969-983.
DR   PDBsum; 4CRS; -.
DR   PDBsum; 4RRV; -.
DR   ProteinModelPortal; Q16513; -.
DR   SMR; Q16513; -.
DR   BioGrid; 111572; 86.
DR   IntAct; Q16513; 50.
DR   MINT; MINT-198348; -.
DR   STRING; 9606.ENSP00000359552; -.
DR   BindingDB; Q16513; -.
DR   ChEMBL; CHEMBL3032; -.
DR   GuidetoPHARMACOLOGY; 1521; -.
DR   iPTMnet; Q16513; -.
DR   PhosphoSitePlus; Q16513; -.
DR   BioMuta; PKN2; -.
DR   DMDM; 6225859; -.
DR   EPD; Q16513; -.
DR   MaxQB; Q16513; -.
DR   PaxDb; Q16513; -.
DR   PeptideAtlas; Q16513; -.
DR   PRIDE; Q16513; -.
DR   DNASU; 5586; -.
DR   Ensembl; ENST00000370513; ENSP00000359544; ENSG00000065243. [Q16513-3]
DR   Ensembl; ENST00000370521; ENSP00000359552; ENSG00000065243. [Q16513-1]
DR   GeneID; 5586; -.
DR   KEGG; hsa:5586; -.
DR   UCSC; uc001dmn.4; human. [Q16513-1]
DR   CTD; 5586; -.
DR   DisGeNET; 5586; -.
DR   GeneCards; PKN2; -.
DR   HGNC; HGNC:9406; PKN2.
DR   HPA; HPA034861; -.
DR   MIM; 602549; gene.
DR   neXtProt; NX_Q16513; -.
DR   OpenTargets; ENSG00000065243; -.
DR   PharmGKB; PA33770; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233032; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q16513; -.
DR   KO; K06071; -.
DR   OMA; PRAPQMN; -.
DR   OrthoDB; EOG091G00YT; -.
DR   PhylomeDB; Q16513; -.
DR   TreeFam; TF102005; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   SignaLink; Q16513; -.
DR   SIGNOR; Q16513; -.
DR   ChiTaRS; PKN2; human.
DR   GeneWiki; PKN2; -.
DR   GenomeRNAi; 5586; -.
DR   PMAP-CutDB; Q16513; -.
DR   PRO; PR:Q16513; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000065243; -.
DR   CleanEx; HS_PKN2; -.
DR   ExpressionAtlas; Q16513; baseline and differential.
DR   Genevisible; Q16513; HS.
DR   GO; GO:0043296; C:apical junction complex; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:AgBase.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:AgBase.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0070063; F:RNA polymerase binding; IPI:AgBase.
DR   GO; GO:0043297; P:apical junction assembly; IMP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0010631; P:epithelial cell migration; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IMP:AgBase.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF02185; HR1; 3.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00742; Hr1; 3.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF46585; SSF46585; 3.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Cell adhesion; Cell cycle; Cell division; Cell junction;
KW   Cell projection; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase.
FT   CHAIN         1    984       Serine/threonine-protein kinase N2.
FT                                /FTId=PRO_0000055722.
FT   REPEAT       44    119       REM 1.
FT   REPEAT      133    213       REM 2.
FT   REPEAT      214    295       REM 3.
FT   DOMAIN      330    463       C2.
FT   DOMAIN      657    916       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      917    984       AGC-kinase C-terminal.
FT   NP_BIND     663    671       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      382    463       Necessary to rescue apical junction
FT                                formation. {ECO:0000250}.
FT   REGION      917    977       Necessary for the catalytic activity.
FT   REGION      978    984       Negatively regulates the responsiveness
FT                                of the catalytic activity by cardiolipin
FT                                and is required for optimal activation by
FT                                the GTP-bound RhoA.
FT   ACT_SITE    782    782       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     686    686       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        117    118       Cleavage; by caspase-3.
FT   SITE        700    701       Cleavage; by caspase-3.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      77     77       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BWW9}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     121    121       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     124    124       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     302    302       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     306    306       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     360    360       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     362    362       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     535    535       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     583    583       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     620    620       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BWW9}.
FT   MOD_RES     628    628       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     816    816       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:10792047}.
FT   MOD_RES     952    952       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     958    958       Phosphothreonine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1    326       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042180.
FT   VAR_SEQ       1    157       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042181.
FT   VAR_SEQ     327    329       LTG -> MNS (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042182.
FT   VAR_SEQ     375    390       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042183.
FT   VAR_SEQ     428    475       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_042184.
FT   VARIANT      94     94       E -> D (in dbSNP:rs12039846).
FT                                /FTId=VAR_050562.
FT   VARIANT     197    197       A -> E (in dbSNP:rs35207128).
FT                                /FTId=VAR_050563.
FT   VARIANT     655    655       Q -> R (in dbSNP:rs12085658).
FT                                /FTId=VAR_050564.
FT   MUTAGEN     117    117       D->A: Prevents proteolytic processing by
FT                                caspase-3 during apoptosis. Diminishes
FT                                pro-apoptotic function; when associated
FT                                with E-700. {ECO:0000269|PubMed:10926925,
FT                                ECO:0000269|PubMed:9368003}.
FT   MUTAGEN     686    686       K->R: Does not inhibit interaction with
FT                                PTPN13. {ECO:0000269|PubMed:11356191}.
FT   MUTAGEN     700    700       D->E: Prevents proteolytic processing by
FT                                caspase-3 during apoptosis. Diminishes
FT                                pro-apoptotic function; when associated
FT                                with A-117. {ECO:0000269|PubMed:10926925,
FT                                ECO:0000269|PubMed:9368003}.
FT   MUTAGEN     816    816       T->A: Reduces catalytic activity.
FT                                {ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     958    958       T->A: Abolishes catalytic activity.
FT                                {ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     974    974       F->A: Abolishes interaction with PDPK1
FT                                and prevents the phosphorylation of AKT1
FT                                at 'Ser-473'.
FT                                {ECO:0000269|PubMed:10226025}.
FT   MUTAGEN     977    977       F->A,L: Abolishes interaction with PDPK1
FT                                and prevents the phosphorylation of AKT1
FT                                at 'Ser-473'. Reduces catalytic activity
FT                                by 90%. {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     977    977       F->W,Y: Reduces catalytic activity by
FT                                50%. {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     978    978       D->A,S: Abolishes interaction with PDPK1
FT                                and prevents the phosphorylation of AKT1
FT                                at 'Ser-473'.
FT                                {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     978    978       D->A: Does not inhibit catalytic
FT                                activity. {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     979    979       Y->A: Abolishes interaction with PDPK1
FT                                and prevents the phosphorylation of AKT1
FT                                at 'Ser-473'.
FT                                {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     979    979       Y->A: Reduces catalytic activity by 50%.
FT                                {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     979    979       Y->F,L,W: Reduces catalytic activity by
FT                                25%. {ECO:0000269|PubMed:10226025,
FT                                ECO:0000269|PubMed:18835241}.
FT   MUTAGEN     984    984       C->S: Inhibits interaction with PTPN13.
FT                                {ECO:0000269|PubMed:11356191}.
FT   CONFLICT    483    483       I -> V (in Ref. 3; BAG62673).
FT                                {ECO:0000305}.
FT   CONFLICT    565    565       K -> R (in Ref. 3; BAG60783).
FT                                {ECO:0000305}.
FT   CONFLICT    625    625       K -> R (in Ref. 3; BAG62673).
FT                                {ECO:0000305}.
FT   CONFLICT    795    795       F -> L (in Ref. 6; AAI25200).
FT                                {ECO:0000305}.
FT   HELIX       647    649       {ECO:0000244|PDB:4CRS}.
FT   STRAND      652    654       {ECO:0000244|PDB:4CRS}.
FT   STRAND      657    665       {ECO:0000244|PDB:4CRS}.
FT   STRAND      670    676       {ECO:0000244|PDB:4CRS}.
FT   STRAND      682    689       {ECO:0000244|PDB:4CRS}.
FT   HELIX       690    695       {ECO:0000244|PDB:4CRS}.
FT   HELIX       699    714       {ECO:0000244|PDB:4CRS}.
FT   STRAND      723    729       {ECO:0000244|PDB:4CRS}.
FT   STRAND      732    738       {ECO:0000244|PDB:4CRS}.
FT   HELIX       745    749       {ECO:0000244|PDB:4CRS}.
FT   HELIX       756    774       {ECO:0000244|PDB:4CRS}.
FT   TURN        775    777       {ECO:0000244|PDB:4CRS}.
FT   HELIX       785    787       {ECO:0000244|PDB:4CRS}.
FT   STRAND      788    790       {ECO:0000244|PDB:4CRS}.
FT   STRAND      796    798       {ECO:0000244|PDB:4CRS}.
FT   STRAND      805    807       {ECO:0000244|PDB:4CRS}.
FT   HELIX       821    823       {ECO:0000244|PDB:4CRS}.
FT   HELIX       826    830       {ECO:0000244|PDB:4CRS}.
FT   HELIX       838    852       {ECO:0000244|PDB:4CRS}.
FT   HELIX       862    871       {ECO:0000244|PDB:4CRS}.
FT   HELIX       882    891       {ECO:0000244|PDB:4CRS}.
FT   HELIX       896    898       {ECO:0000244|PDB:4CRS}.
FT   STRAND      903    905       {ECO:0000244|PDB:4CRS}.
FT   HELIX       907    911       {ECO:0000244|PDB:4CRS}.
FT   HELIX       914    916       {ECO:0000244|PDB:4CRS}.
FT   HELIX       921    925       {ECO:0000244|PDB:4CRS}.
FT   STRAND      944    946       {ECO:0000244|PDB:4CRS}.
FT   HELIX       948    951       {ECO:0000244|PDB:4CRS}.
SQ   SEQUENCE   984 AA;  112035 MW;  687EC417A0F51C1D CRC64;
     MASNPERGEI LLTELQGDSR SLPFSENVSA VQKLDFSDTM VQQKLDDIKD RIKREIRKEL
     KIKEGAENLR KVTTDKKSLA YVDNILKKSN KKLEELHHKL QELNAHIVVS DPEDITDCPR
     TPDTPNNDPR CSTSNNRLKA LQKQLDIELK VKQGAENMIQ MYSNGSSKDR KLHGTAQQLL
     QDSKTKIEVI RMQILQAVQT NELAFDNAKP VISPLELRME ELRHHFRIEF AVAEGAKNVM
     KLLGSGKVTD RKALSEAQAR FNESSQKLDL LKYSLEQRLN EVPKNHPKSR IIIEELSLVA
     ASPTLSPRQS MISTQNQYST LSKPAALTGT LEVRLMGCQD ILENVPGRSK ATSVALPGWS
     PSETRSSFMS RTSKSKSGSS RNLLKTDDLS NDVCAVLKLD NTVVGQTSWK PISNQSWDQK
     FTLELDRSRE LEISVYWRDW RSLCAVKFLR LEDFLDNQRH GMCLYLEPQG TLFAEVTFFN
     PVIERRPKLQ RQKKIFSKQQ GKTFLRAPQM NINIATWGRL VRRAIPTVNH SGTFSPQAPV
     PTTVPVVDVR IPQLAPPASD STVTKLDFDL EPEPPPAPPR ASSLGEIDES SELRVLDIPG
     QDSETVFDIQ NDRNSILPKS QSEYKPDTPQ SGLEYSGIQE LEDRRSQQRF QFNLQDFRCC
     AVLGRGHFGK VLLAEYKNTN EMFAIKALKK GDIVARDEVD SLMCEKRIFE TVNSVRHPFL
     VNLFACFQTK EHVCFVMEYA AGGDLMMHIH TDVFSEPRAV FYAACVVLGL QYLHEHKIVY
     RDLKLDNLLL DTEGFVKIAD FGLCKEGMGY GDRTSTFCGT PEFLAPEVLT ETSYTRAVDW
     WGLGVLIYEM LVGESPFPGD DEEEVFDSIV NDEVRYPRFL STEAISIMRR LLRRNPERRL
     GASEKDAEDV KKHPFFRLID WSALMDKKVK PPFIPTIRGR EDVSNFDDEF TSEAPILTPP
     REPRILSEEE QEMFRDFDYI ADWC
//
